# Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing

> **NCT02805556** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 36 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** BMS-663068
- **DRUG:** BMS-626529

## Key facts

- **NCT ID:** NCT02805556
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-15
- **Primary completion:** 2016-05-05
- **Final completion:** 2016-05-05
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02805556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02805556, "Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02805556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*